363 related articles for article (PubMed ID: 30779338)
21. [Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia].
Weng M; Li L; Feng S; Xie M; Hong S
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1350-4. PubMed ID: 22985581
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
Baker J; Obermair A; Gebski V; Janda M
Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
[TBL] [Abstract][Full Text] [Related]
23. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
24. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
Pal N; Broaddus RR; Urbauer DL; Balakrishnan N; Milbourne A; Schmeler KM; Meyer LA; Soliman PT; Lu KH; Ramirez PT; Ramondetta L; Bodurka DC; Westin SN
Obstet Gynecol; 2018 Jan; 131(1):109-116. PubMed ID: 29215513
[TBL] [Abstract][Full Text] [Related]
26. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
[TBL] [Abstract][Full Text] [Related]
27. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
28. Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy.
Travaglino A; Raffone A; Saccone G; Mascolo M; D'Alessandro P; Arduino B; Mollo A; Insabato L; Zullo F
APMIS; 2019 Nov; 127(11):699-709. PubMed ID: 31403731
[TBL] [Abstract][Full Text] [Related]
29. Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019).
Kim MK; Seong SJ; Lee TS; Ki KD; Lim MC; Kim YH; Kim K; Joo WD
Jpn J Clin Oncol; 2015 Oct; 45(10):980-2. PubMed ID: 26206899
[TBL] [Abstract][Full Text] [Related]
30. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
[TBL] [Abstract][Full Text] [Related]
31. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
32. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
Kim MK; Seong SJ; Park DC; Hong JH; Roh JW; Kang SB
J Gynecol Oncol; 2020 Jul; 31(4):e51. PubMed ID: 32266800
[TBL] [Abstract][Full Text] [Related]
33. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Shao F; Li Y; Zhao Y
Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
[TBL] [Abstract][Full Text] [Related]
34. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Kim NK; Choi CH; Seong SJ; Lee JM; Lee B; Kim K
Gynecol Oncol; 2024 Apr; 183():68-73. PubMed ID: 38520881
[TBL] [Abstract][Full Text] [Related]
36. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
38. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
39. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
